CD274 and non-small cell lung carcinoma: For example, in patients with newly diagnosed advanced non-small cell lung cancers and ≥ 50% PD-L1 expression, the combination of chemotherapy plus anti-PD-1 treatment with pembrolizumab significantly improved their objective response rate, progression-free survival, and overall survival [72].